FSHR 基因多态性对预测正常反应者晚卵泡期孕酮和雌二醇血清水平的影响
这项多中心跨国前瞻性研究纳入366例预测正常反应者,采用固定每日150 IU rFSH的GnRH拮抗剂方案,发现FSHR SNPs(rs6165、rs6166、rs1394205)对晚卵泡期血清孕酮和雌二醇水平无临床显著影响。
要点
- FSHR SNPs rs6165、rs6166、rs1394205对预测正常反应者晚卵泡期孕酮和雌二醇无临床显著影响。
- 晚卵泡期孕酮升高总体患病率为15.8%(n=58),白种人与亚洲患者间无显著差异。
- rs6166/rs6165单倍型GA、AA、GG的扳机日雌二醇水平显著低于AG。
核心结论
- FSHR SNPs rs6165、rs6166和rs1394205对预测正常反应者晚卵泡期血清孕酮和雌二醇水平均无临床显著影响。
研究设计与样本
- 多中心跨国前瞻性研究,2016年11月至2019年6月纳入越南、比利时和西班牙366例患者(欧洲166例,亚洲200例)。
- 纳入患者为<38岁、接受第一或第二周期卵巢刺激的预测正常反应者,采用固定每日150 IU rFSH的GnRH拮抗剂方案。
- 所有患者对3个FSHR SNPs(rs6165、rs6166、rs1394205)进行基因分型,并在扳机日测定血清孕酮和雌二醇。
主要发现
- 晚卵泡期孕酮升高总体患病率为15.8%(n=58),白种人与亚洲患者间无显著差异(17.5% vs 14.5%)。
- 孕酮升高患者扳机日雌二醇水平显著高于无孕酮升高者(4779 ± 6236.2 vs 3261 ± 3974.5 pg/ml,P = 0.003)。
- 孕酮升高患者获卵数显著多于无孕酮升高者(16.1 ± 8.02 vs 13.5 ± 6.66,P = 0.011)。
- 双变量分析中,FSHR rs6166(P = 0.941)、rs6165(P = 0.637)、rs1394205(P = 0.114)各基因型间晚卵泡期平均孕酮水平无统计学显著差异。
- 单倍型分析显示,rs6166/rs6165单倍型GA、AA、GG的扳机日雌二醇水平显著低于AG,估计平均差值分别为-441.46 pg/ml(95% CI -442.47; -440.45)、-673.46 pg/ml(95% CI -674.26; -672.67)、-582.10 pg/ml(95% CI -584.92; -579.28)。
关键数值与推荐
- 孕酮升高定义为>1.50 ng/ml。
- 遗传模型分析校正了患者年龄、体重指数、获卵数和所在洲(亚洲 vs 欧洲)。
- rs6166/rs6165单倍型分析中,GA、AA、GG与AG相比扳机日雌二醇估计平均差值分别为-441.46 pg/ml(95% CI -442.47; -440.45)、-673.46 pg/ml(95% CI -674.26; -672.67)、-582.10 pg/ml(95% CI -584.92; -579.28)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 结果仅适用于整个卵巢刺激周期接受固定150 IU rFSH正常/低剂量治疗的预测正常反应者人群,推广至所有患者类别前需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the presence of FSHR single-nucleotide polymorphisms (SNPs) affect late follicular phase progesterone and estradiol serum levels in predicted normoresponders treated with rFSH? SUMMARY ANSWER: The presence of FSHR SNPs (rs6165, rs6166, rs1394205) had no clinically significant impact on late follicular phase serum progesterone and estradiol levels in predicted normoresponders undergoing a GnRH antagonist protocol with a fixed daily dose of 150 IU rFSH. WHAT IS KNOWN ALREADY: Previous studies have shown that late follicular phase serum progesterone and estradiol levels are significantly correlated with the magnitude of ovarian response. Several authors have proposed that individual variability in the response to ovarian stimulation (OS) could be explained by variants in FSHR. However, so far, the literature is scarce on the influence of this genetic variability on late follicular phase steroidogenic response. Our aim is to determine whether genetic variants in the FSHR gene could modulate late follicular phase serum progesterone and estradiol levels. STUDY DESIGN, SIZE, DURATION: In this multicenter multinational prospective study conducted from November 2016 to June 2019, 366 patients from Vietnam, Belgium and Spain (166 from Europe and 200 from Asia) underwent OS followed by oocyte retrieval in a GnRH antagonist protocol with a fixed daily dose of 150 IU rFSH. All patients were genotyped for 3 FSHR SNPs (rs6165, rs6166, rs1394205) and had a serum progesterone and estradiol measurement on the day of trigger. PARTICIPANTS/MATERIALS, SETTING, METHODS: Included patients were predicted normal responder women <38 years old undergoing their first or second OS cycle. The prevalence of late follicular phase progesterone elevation (PE), as well as mean serum progesterone and estradiol levels on the day of trigger were compared between the different FSHR SNPs genotypes. PE was defined as >1.50 ng/ml. MAIN RESULTS AND THE ROLE OF CHANCE: The overall prevalence of PE was 15.8% (n = 58). No significant difference was found in the prevalence of PE in Caucasian and Asian patients (17.5% versus 14.5%). Estradiol levels on the day of trigger and the number of retrieved oocytes were significantly higher in patients with PE (4779 ± 6236.2 versus 3261 ± 3974.5 pg/ml, P = 0.003, and 16.1 ± 8.02 versus 13.5 ± 6.66, P = 0.011, respectively). Genetic model analysis, adjusted for patient age, body mass index, number of retrieved oocytes and continent (Asia versus Europe), revealed a similar prevalence of PE in co-dominant, dominant and recessive models for variants FSHR rs6166, rs6165 and rs1394205. No statistically significant difference was observed in the mean late follicular phase progesterone serum levels according to the genotypes of FSHR rs6166 (P = 0.941), rs6165 (P = 0.637) and rs1394205 (P = 0.114) in the bivariate analysis. Also, no difference was found in the genetic model analysis regarding mean late follicular phase progesterone levels across the different genotypes. Genetic model analysis has also revealed no statistically significant difference regarding mean estradiol levels on the day of trigger in co-dominant, dominant and recessive models for variants FSHR rs6166, rs6165 and rs1394205. Haplotype analysis revealed a statistically significant lower estradiol level on the day of trigger for rs6166/rs6165 haplotypes GA, AA and GG when compared to AG (respectively, estimated mean difference (EMD) -441.46 pg/ml (95% CI -442.47; -440.45), EMD -673.46 pg/ml (95% CI -674.26; -672.67) and EMD -582.10 pg/ml (95% CI -584.92; -579.28)). No statistically significant differences were found regarding the prevalence of PE nor late follicular phase progesterone levels according to rs6166/rs6165 haplotypes. LIMITATIONS, REASONS FOR CAUTION: Results refer to a population of predicted normal responders treated with a normal/low fixed dose of 150 IU rFSH throughout the whole OS. Consequently, caution is needed before generalizing our results to all patient categories. WIDER IMPLICATIONS OF THE FINDINGS: Based on our results, FSHR SNPs rs6165, rs6166 and rs1394205 do not have any clinically significant impact neither on late follicular phase serum progesterone nor on estradiol levels in predicted normal responders. These findings add to the controversy in the literature regarding the impact of individual genetic susceptibility in response to OS in this population. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by an unrestricted grant by Merck Sharp & Dohme (MSD, IISP56222). N.P.P. reports grants and/or personal fees from MSD, Merck Serono, Roche Diagnostics, Ferring International, Besins Healthcare, Gedeon Richter, Organon, Theramex and Institut Biochimique SA (IBSA). C.A. reports conference fees from Merck Serono, Medea and Event Planet. A.R.N., C.B., C.S., P.Q.M.M., H.T., C.B., N.L.V., M.T.H. and S.G. report no conflict of interests related to the content of this article. TRIAL REGISTRATION NUMBER: NCT03007043.
引用
- Neves AR, Vuong NL, Blockeel C, et al. The effect of polymorphisms in FSHR gene on late follicular phase progesterone and estradiol serum levels in predicted normoresponders. Hum Reprod. 2022. PMID: 36069495. doi:10.1093/humrep/deac193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。